This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/kegg-compound/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/kegg-drug/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01330/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01330
rdf:type
n3:Drug
n3:description
A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]
n3:dosage
n22:271B3F1E-363D-11E5-9242-09173F13E4C5 n22:271B3F1F-363D-11E5-9242-09173F13E4C5 n22:271B3F20-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged
n3:indication
For prophylaxis and treatment of bacterial infections.
owl:sameAs
n7:DB01330 n23:DB01330
dcterms:title
Cefotetan
adms:identifier
n9:3499 n10:PA164784033 n11:D00260 n12:Cefotetan n13:0310-0376-31 n14:DB01330 n15:C06886
n3:mechanismOfAction
The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.
n3:packager
n4:271B3F16-363D-11E5-9242-09173F13E4C5 n4:271B3F17-363D-11E5-9242-09173F13E4C5 n4:271B3F15-363D-11E5-9242-09173F13E4C5 n4:271B3F18-363D-11E5-9242-09173F13E4C5 n4:271B3F19-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.
n3:synonym
(6R,7S)-7-(4-(Carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid Cefotetanum
n3:volumeOfDistribution
* 10.4 L [elderly patients (greater than 65 years) with normal renal function] * 10.3 L [healthy volunteers (aged 25 to 28 years)]
n3:foodInteraction
Avoid alcohol as it can cause a disulfiram effect.
n3:proteinBinding
Cefotetan is 88% plasma protein bound.
n3:synthesisReference
Maurizio Zenoni, "Process for obtaining compounds usable in the production of Cefotetan, and new compounds obtained thereby." U.S. Patent US20020169327, issued November 14, 2002.
n24:hasConcept
n25:M0023580
foaf:page
n20:cefotet.htm n26:cefotetan.html
n3:IUPAC-Name
n5:271B3F25-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B3F2B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B3F2A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3F27-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B3F28-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B3F29-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B3F23-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B3F24-363D-11E5-9242-09173F13E4C5 n5:271B3F21-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B3F22-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J01DC05
n3:H-Bond-Acceptor-Count
n5:271B3F31-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B3F32-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B3F2C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B3F2D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B3F2F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B3F2E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B3F30-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
69712-56-7
n3:category
n3:clearance
* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] * 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]
n3:containedIn
n16:271B3F1B-363D-11E5-9242-09173F13E4C5 n16:271B3F1C-363D-11E5-9242-09173F13E4C5 n16:271B3F1D-363D-11E5-9242-09173F13E4C5 n16:271B3F1A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B3F37-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B3F39-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B3F3A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B3F36-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B3F35-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B3F38-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B3F26-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B3F33-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B3F34-363D-11E5-9242-09173F13E4C5